Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies. Shionogi markets cefiderocol (Fetroja) for complicated urinary tract infections, an investigational oral antiviral for COVID-19, and a range of influenza treatments. It also collaborates with international partners on HIV integrase inhibitors and oncology agents, leveraging strategic alliances to accelerate global development and distribution.

Headquartered in Osaka, Shionogi maintains research facilities and subsidiaries across Asia, North America and Europe. Its network of laboratories focuses on discovery science, translational research and clinical development, while manufacturing sites in Japan and abroad ensure supply chain resilience and regulatory compliance in multiple regions.

Governed by a board of directors and led by a President & Representative Director, Shionogi continues to invest heavily in R&D, with a pipeline targeting antimicrobial resistance, metabolic diseases and novel immunotherapies. Its unsponsored American depositary receipt trades on the OTC Market under the ticker SGIOY, providing U.S. investors access to its evolving business.

Key Stats

• Today's Range: $9.11 to $9.31
• 50-Day Range: $8.79 to $11.41
• 52-Week Range: $7.65 to $12.00
• Volume: 39,870 shs
• Average Volume: 114,872 shs
• Market Capitalization: $15.78 billion
• P/E Ratio: 11.59
• Dividend Yield: 1.40%
• Price Target: N/A
• Consensus Rating: Reduce

Shionogi & Co., Ltd. Unsponsored ADR Stock Analysis - MarketRank™

Shionogi & Co., Ltd. Unsponsored ADR scored higher than 45% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Shionogi & Co., Ltd. Unsponsored ADR has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Shionogi & Co., Ltd. Unsponsored ADR has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 2.56%

Earnings Growth

Earnings for Shionogi & Co., Ltd. Unsponsored ADR are expected to grow by 2.56% in the coming year, from $0.78 to $0.80 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 11.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.52.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. Unsponsored ADR is 11.59, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.

Price to Earnings Growth Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a PEG Ratio of 0.70. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Shionogi & Co., Ltd. Unsponsored ADR has a P/B Ratio of 1.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Shionogi & Co., Ltd. Unsponsored ADR has been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. Unsponsored ADR has a short interest ratio ("days to cover") of 0.08, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. Unsponsored ADR has recently increased by 100.90%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Shionogi & Co., Ltd. Unsponsored ADR pays a meaningful dividend of 1.34%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. Unsponsored ADR does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. Unsponsored ADR is 16.25%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Shionogi & Co., Ltd. Unsponsored ADR will have a dividend payout ratio of 16.25% next year. This indicates that Shionogi & Co., Ltd. Unsponsored ADR will be able to sustain or increase its dividend.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. Unsponsored ADR insiders have not sold or bought any company stock.

Percentage Held by Institutions

1.92% of the stock of Shionogi & Co., Ltd. Unsponsored ADR is held by institutions.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 5/21/2026
• Next Earnings (Estimated): 7/27/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOY
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 4,955
• Year Founded: 1878

Profitability

• EPS (Trailing Twelve Months): $0.80
• Trailing P/E Ratio: 11.59
• Forward P/E Ratio: 11.88
• P/E Growth: 0.7
• Net Income: $1.36 billion
• Net Margins: 41.08%
• Pretax Margin: N/A
• Return on Equity: 14.09%
• Return on Assets: 12.50%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.84
• Quick Ratio: 5.21

Sales & Book Value

• Annual Sales: $3.32 billion
• Price / Sales: 4.75
• Cash Flow: $0.72 per share
• Price / Cash Flow: 12.79
• Book Value: $5.29 per share
• Price / Book: 1.75

Miscellaneous

• Outstanding Shares: 1,701,950,000
• Free Float: N/A
• Market Cap: $15.78 billion
• Optionable: Not Optionable
• Beta: 0.10